이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

TSC1 또는 TSC2 유전자에 병원성 변화가 있는 악성 고형 종양 환자에서 Nab-sirolimus의 2상 바구니 실험(PRECISION 1)

2026년 10월 26일 업데이트: Aadi Bioscience, Inc.

TSC1 또는 TSC2 유전자의 병원성 불활성화 변이가 있는 악성 고형 종양이 있는 성인 및 청소년 환자를 대상으로 한 Nab-sirolimus의 2상 다기관 공개 라벨 바스켓 시험

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

Study TSC-007 is a prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety profile of nab-sirolimus administered to patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. Patients will be treated with single agent IV nab-sirolimus until disease progression, or unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion.

연구 유형

중재적

등록 (실제)

128

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 대한민국
      • Busan, 대한민국, 48108
        • Inje University Haeundae Paik Hospital
      • Seoul, 대한민국, 03080
        • Seoul National University Hospital
      • Seoul, 대한민국, 05505
        • Asan Medical Center
      • Seoul, 대한민국, 06351
        • Samsung Medical Center
      • Seoul, 대한민국, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, 대한민국, 08308
        • Korea University Guro Hospital
  • 미국
    • Alabama
      • Birmingham, Alabama, 미국, 35243
        • Alabama Oncology
      • Mobile, Alabama, 미국, 36607
        • Southern Cancer Center
    • Arizona
      • Goodyear, Arizona, 미국, 85395
        • Arizona Oncology Associates
      • Phoenix, Arizona, 미국, 85016
        • Honor Health
      • Prescott Valley, Arizona, 미국, 86301
        • Arizona Oncology Associates
      • Yuma, Arizona, 미국, 85364
        • Yuma Regional Medical Center
    • California
      • Arroyo Grande, California, 미국, 93420
        • PCR Oncology
      • Beverly Hills, California, 미국, 90212
        • Nextgen Oncology
      • Duarte, California, 미국, 91010
        • City of Hope
      • Fullerton, California, 미국, 92835
        • Providence Medical Foundation (Fullerton)
      • Long Beach, California, 미국, 90806
        • MemorialCare
      • Los Angeles, California, 미국, 90033
        • USC Norris Comprehensive Cancer Center
      • Los Angeles, California, 미국, 90095
        • UCLA - Jonsson Comprehensive Cancer Center
      • Napa, California, 미국, 94558
        • Providence Medical Foundation (Napa)
      • Newport Beach, California, 미국, 92663
        • Hoag Memorial Hospital Presbyterian
      • San Diego, California, 미국, 92123
        • Sharp HealthCare
      • San Francisco, California, 미국, 94115
        • UCSF Helen Diller Family Comprehensive Cancer Center
      • Santa Barbara, California, 미국, 93105
        • Ridley-Tree Cancer Center
      • Santa Monica, California, 미국, 90403
        • Sarcoma Oncology Research Center
      • Santa Rosa, California, 미국, 95403
        • Providence Medical Foundation
      • Stanford, California, 미국, 94305
        • Stanford Cancer Center
      • Whittier, California, 미국, 90602
        • The Oncology Institute of Hope & Innovation
    • Colorado
      • Aurora, Colorado, 미국, 80012
        • Rocky Mountain Cancer Centers
      • Boulder, Colorado, 미국, 80303
        • Rocky Mountain Cancer Centers
      • Colorado Springs, Colorado, 미국, 80907
        • Rocky Mountain Cancer Centers
      • Denver, Colorado, 미국, 80220
        • Rocky Mountain Cancer Centers
      • Denver, Colorado, 미국, 80218
        • Rocky Mountain Cancer Centers (Williams St)
      • Lakewood, Colorado, 미국, 80228
        • Rocky Mountain Cancer Centers
      • Littleton, Colorado, 미국, 80120
        • Rocky Mountain Cancer Centers
      • Lone Tree, Colorado, 미국, 80124
        • Rocky Mountain Cancer Centers
      • Longmont, Colorado, 미국, 80501
        • Rocky Mountain Cancer Centers
      • Pueblo, Colorado, 미국, 81008
        • Rocky Mountain Cancer Centers
      • Thornton, Colorado, 미국, 80260
        • Rocky Mountain Cancer Centers
    • Connecticut
      • Hartford, Connecticut, 미국, 06102
        • Hartford Healthcare
      • Norwich, Connecticut, 미국, 06360
        • Eastern Connecticut Hematology and Oncology
    • Florida
      • Altamonte Springs, Florida, 미국, 32701
        • Florida Cancer Specialists - North Division
      • Bonita Springs, Florida, 미국, 34135
        • Florida Cancer Specialists - South Division
      • Bradenton, Florida, 미국, 34205
        • Florida Cancer Specialists - South Division
      • Bradenton, Florida, 미국, 34211
        • Florida Cancer Specialists - South Division
      • Brandon, Florida, 미국, 33511
        • Florida Cancer Specialists - North Division
      • Cape Coral, Florida, 미국, 33909
        • Florida Cancer Specialists - South Division
      • Clearwater, Florida, 미국, 33761
        • Florida Cancer Specialists - North Division
      • Daytona Beach, Florida, 미국, 32117
        • Cancer Specialist - East
      • Fort Lauderdale, Florida, 미국, 33308
        • Holy Cross Hospital
      • Fort Myers, Florida, 미국, 33901
        • Florida Cancer Specialists South Division
      • Fort Myers, Florida, 미국, 33905
        • Florida Cancer Specialists - South
      • Fort Myers, Florida, 미국, 33908
        • Florida Cancer Specialists - South
      • Gainesville, Florida, 미국, 32605
        • Florida Cancer Specialists - North Division
      • Jacksonville, Florida, 미국, 32256
        • Cancer Specialists of North Florida
      • Lakeland, Florida, 미국, 33812
        • TOI Florida
      • Lakeland, Florida, 미국, 33812
        • The Oncology Institute of Hope and Innovation
      • Largo, Florida, 미국, 33770
        • Florida Cancer Specialists - North Division
      • Lecanto, Florida, 미국, 34461
        • Florida Cancer Specialists - North Division
      • Naples, Florida, 미국, 34102
        • Florida Cancer Specialists - South Division
      • Ocala, Florida, 미국, 34474
        • Ocala Oncology
      • Ocala, Florida, 미국, 34474
        • Florida Cancer Specialists - North Division
      • Orange City, Florida, 미국, 32763
        • Florida Cancer Specialists - North Division
      • Orlando, Florida, 미국, 32806
        • Florida Cancer Specialists - North Division
      • Port Charlotte, Florida, 미국, 33980
        • Florida Cancer Specialists - South Division
      • Sarasota, Florida, 미국, 34232
        • Florida Cancer Specialists - South Division
      • Sarasota, Florida, 미국, 34236
        • Florida Cancer Specialists - South Division
      • St. Petersburg, Florida, 미국, 33705
        • Florida Cancer Specialists and Research Institute - North Division
      • St. Petersburg, Florida, 미국, 33707
        • Florida Cancer Specialists - North
      • Stuart, Florida, 미국, 34994
        • Florida Cancer Specialist - East
      • Tampa, Florida, 미국, 33607
        • Florida Cancer Specialists - North Division
      • Tavares, Florida, 미국, 32778
        • Florida Cancer Specialists - North Division
      • Trinity, Florida, 미국, 34655
        • Florida Cancer Specialists - North Division
      • Venice, Florida, 미국, 34285
        • Florida Cancer Specialists - South Division
      • Venice, Florida, 미국, 34292
        • Florida Cancer Specialists - South Division
      • Vero Beach, Florida, 미국, 32960
        • Florida Cancer Specialists - East
      • Wellington, Florida, 미국, 33414
        • Florida Cancer Specialists - East
      • West Palm Beach, Florida, 미국, 33401
        • Florida Cancer Specialists - East
    • Georgia
      • Atlanta, Georgia, 미국, 30303
        • Morehouse School of Medicine
    • Hawaii
      • Honolulu, Hawaii, 미국, 96813
        • Hawaii Cancer Center
    • Illinois
      • Hinsdale, Illinois, 미국, 60521
        • Hope and Healing Cancer Services
      • Rolling Meadows, Illinois, 미국, 60008
        • Northwest Oncology and Hematology
    • Indiana
      • Carmel, Indiana, 미국, 46032
        • Urology of Indiana
      • Fort Wayne, Indiana, 미국, 46804
        • Fort Wayne Medical Oncology and Hematology
      • Goshen, Indiana, 미국, 46526
        • Goshen Health
    • Louisiana
      • Baton Rouge, Louisiana, 미국, 70817
        • Our Lady of the Lake
      • Hammond, Louisiana, 미국, 70403
        • Pontchartrain
    • Maryland
      • Bethesda, Maryland, 미국, 20817
        • American Oncology Partners of Maryland PA (Center for Cancer & Blood Disorders)
      • Frederick, Maryland, 미국, 21702
        • Frederick Health
      • Rockville, Maryland, 미국, 20850
        • Maryland Oncology Hematology
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • Dana Farber Cancer Institute
      • Fairhaven, Massachusetts, 미국, 02719
        • Southcoast Centers for Cancer Care
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • Barbara Ann Karmanos Cancer Institute
      • Lansing, Michigan, 미국, 48912
        • Sparrow Hospital
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55404
        • Minnesota Oncology Hematology
    • Missouri
      • Bolivar, Missouri, 미국, 65613
        • Central Care Cancer Center
      • Osage Beach, Missouri, 미국, 65065
        • Lake Regional
      • Saint Joseph, Missouri, 미국, 64507
        • Mosaic Life Care
      • Springfield, Missouri, 미국, 65807
        • Oncology Hematology Associates
      • St Louis, Missouri, 미국, 63110
        • Washington University School of Medicine
    • Nebraska
      • Grand Island, Nebraska, 미국, 68803
        • Nebraska Cancer Specialists
      • Omaha, Nebraska, 미국, 68114
        • Nebraska Methodist Hospital
    • Nevada
      • Las Vegas, Nevada, 미국, 89169
        • Comprehensive Cancer Centers of Nevada
      • Las Vegas, Nevada, 미국, 89102
        • OptumCare Cancer Care-Parent
    • New Jersey
      • Belleville, New Jersey, 미국, 07109
        • New Jersey Cancer Care and Blood Disorders
      • Englewood, New Jersey, 미국, 07631
        • Englewood Hospital and Medical Center
      • Florham Park, New Jersey, 미국, 07932
        • Summit Medical Group - NJ
      • Morristown, New Jersey, 미국, 07960
        • Atlantic Health System - Morristown Medical Center
    • New York
      • Buffalo, New York, 미국, 14263
        • Roswell Park Comprehensive Cancer Center
      • East Syracuse, New York, 미국, 13057
        • HOACNY
      • Ithaca, New York, 미국, 14850
        • Cayuga Medical Center
      • New York, New York, 미국, 10065
        • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Goldsboro, North Carolina, 미국, 27534
        • Southeastern Medical Oncology
    • North Dakota
      • Fargo, North Dakota, 미국, 58102
        • Sanford Health-Fargo
    • Ohio
      • Canton, Ohio, 미국, 44708
        • Aultman Medical Group
      • Cincinnati, Ohio, 미국, 45220
        • TriHealth
      • Cincinnati, Ohio, 미국, 45627
        • University of Cincinnati (UC) - Cancer Institute
      • Cleveland, Ohio, 미국, 44195
        • Cleveland Clinic
      • Toledo, Ohio, 미국, 43623
        • The Toledo Clinic
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • Oklahoma State University (OSU) - Stephenson Cancer Center
      • Tulsa, Oklahoma, 미국, 74146
        • Oklahoma Cancer Specialist
    • Pennsylvania
      • Gettysburg, Pennsylvania, 미국, 17325
        • Gettysburg-PCSRI
      • Langhorne, Pennsylvania, 미국, 19047
        • Alliance Cancer Specialists
      • Philadelphia, Pennsylvania, 미국, 19107
        • Thomas Jefferson University
      • York, Pennsylvania, 미국, 17403
        • Cancer Care Associates of York - Parent
    • South Carolina
      • Greenville, South Carolina, 미국, 29605
        • Prisma Health Cancer Institute
    • South Dakota
      • Sioux Falls, South Dakota, 미국, 57105
        • Avera Cancer Institute
      • Sioux Falls, South Dakota, 미국, 57117
        • Sanford Health
    • Tennessee
      • Dickson, Tennessee, 미국, 37055
        • Sarah Cannon and HCA Research Institute
      • Franklin, Tennessee, 미국, 37067
        • Sarah Cannon and HCA Research Institute
      • Gallatin, Tennessee, 미국, 37066
        • Sarah Cannon and HCA Research Institute
      • Germantown, Tennessee, 미국, 38138
        • West Cancer Center
      • Henderson, Tennessee, 미국, 37075
        • Sarah Cannon and HCA Research Institute
      • Hermitage, Tennessee, 미국, 37076
        • Sarah Cannon and HCA Research Institute
      • Lebanon, Tennessee, 미국, 37090
        • Sarah Cannon and HCA Research Institute
      • Memphis, Tennessee, 미국, 38120
        • Baptist Cancer Center
      • Murfreesboro, Tennessee, 미국, 37129
        • Sarah Cannon and HCA Research Institute
      • Nashville, Tennessee, 미국, 37203
        • Sarah Cannon and HCA Research Institute
      • Nashville, Tennessee, 미국, 37205
        • Sarah Cannon and HCA Research Institute
      • Nashville, Tennessee, 미국, 37207
        • Sarah Cannon and HCA Research Institute
      • Nashville, Tennessee, 미국, 37211
        • Sarah Cannon and HCA Research Institute
      • Shelbyville, Tennessee, 미국, 37160
        • Sarah Cannon and HCA Research Institute
      • Smyrna, Tennessee, 미국, 37167
        • Sarah Cannon and HCA Research Institute
    • Texas
      • Dallas, Texas, 미국, 75230
        • Mary Crowley Cancer Research
      • Dallas, Texas, 미국, 75246
        • Texas Oncology - DFW
      • El Paso, Texas, 미국, 79915
        • Texas Oncology
      • Houston, Texas, 미국, 77030
        • MD Anderson Cancer Center
      • Houston, Texas, 미국, 77030
        • Oncology Consultants
      • Irving, Texas, 미국, 75063
        • Arizona Oncology Associates
      • Kingwood, Texas, 미국, 77339
        • Lumi Research
      • McAllen, Texas, 미국, 78503
        • Texas Oncology Central-South
      • San Antonio, Texas, 미국, 78229
        • South Texas Accelerated Research Therapeutics (START)
      • Tyler, Texas, 미국, 75702
        • Texas Oncology
    • Utah
      • Ogden, Utah, 미국, 84405
        • Community Cancer Trials of Utah
      • Salt Lake City, Utah, 미국, 84106
        • Utah Cancer Specialists
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Virginia Cancer Specialists
      • Fredericksburg, Virginia, 미국, 22408
        • Hematology Oncology Associates of Fredericksburg
      • Richmond, Virginia, 미국, 23235
        • Virginia Urology
    • Washington
      • Seattle, Washington, 미국, 98109
        • University of Washington Cancer Consortium
      • Spokane, Washington, 미국, 99216
        • Cancer Care Northwest
      • Spokane, Washington, 미국, 99202
        • Spokane Urology
      • Tacoma, Washington, 미국, 98405
        • Northwest Medical Specialties
    • Wisconsin
      • Appleton, Wisconsin, 미국, 54911
        • ThedaCare
      • La Crosse, Wisconsin, 미국, 54601
        • Gunderson Health System
      • Madison, Wisconsin, 미국, 53705
        • University of Wisconsin - Carbone Cancer Center
  • 푸에르토 리코
    • Puerto Rico
      • San Juan, Puerto Rico, 푸에르토 리코, 00935
        • Pan Oncology Trials, LLC

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

12년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Patients must have a malignant solid tumor with a pathogenic inactivating TSC1 or TSC2 alteration. Genetic alterations should be identified using NGS in tumor tissue or liquid biopsy).

    • Patients will be enrolled after the central evaluation of NGS report confirms eligibility.

  2. Patients must have solid tumors that are metastatic or locally advanced where surgical resection is not an option or likely to result in severe morbidity.

  3. Patients must have received all standard therapies appropriate for their tumor type and stage of disease or, in the opinion of the Investigator, the patient would be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy, or the patient has no satisfactory alternative treatments.

  4. Patients must have 1 or more measurable target lesions by computed tomography (CT) scan or magnetic resonance imaging (MRI) (RECIST v1.1).

  5. Age: 12 years or older.

  6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or Karnofsky Performance Status (KPS) ≥80 or Lansky play-performance scale for pediatric patients ≥80.

  7. Adequate liver function:

    1. Total bilirubin ≤1.5 × upper limit of normal (ULN) (unless due to Gilbert's syndrome, then ≤3 × ULN)
    2. Aspartate aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases)

  8. Adequate renal function: creatinine clearance ≥30 mL/min, Cockcroft-Gault CCr = ((140-age) × weight[kg]) / (72 × SCr[mL/min]) × 0.85, if female

  9. Adequate hematologic parameters:

    1. Absolute neutrophil count (ANC) ≥1.0 × 109/L (growth factor support allowed)
    2. Platelet count ≥100,000/mm3 (100 × 109/L) (transfusion and/or growth factor support allowed)
    3. Hemoglobin ≥8.0 g/dL (transfusion and/or growth factor support allowed)

  10. Fasting serum triglyceride must be ≤300 mg/dL; fasting serum cholesterol must be ≤350 mg/dL.

  11. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of prior systemic anticancer therapy, or at least 5 half-lives if the prior therapy is a single agent small-molecule therapeutic, and adequately recovered from the acute toxicities of any prior therapy, including neuropathy, to Grade ≤1.

  12. Male or non-pregnant and non-breastfeeding female:

    1. Females of childbearing potential must agree to use effective contraception or abstinence without interruption from 28 days prior to starting investigational product (IP) throughout 3 months after last dose of IP and have a negative serum pregnancy test (beta human chorionic gonadotropin, β-hCG) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment. A second form of birth control is required even if she has had a tubal ligation.
    2. Male patients must agree not to donate sperm and must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after last dose of IP. A second form of birth control is required even if he has undergone a successful vasectomy.

  13. The patient or the patient's parent(s) or legal guardian(s) understand(s) and sign(s) the informed consent.

  14. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures.

Exclusion Criteria:

  1. Prior treatment with an mTOR inhibitor, including nab-sirolimus.

  2. Severe (Grade ≥3) ongoing infection requiring parenteral or oral anti-infective treatment, either ongoing or completed ≤7 days prior to enrollment.

  3. Patients with primary brain tumors or PEComa.

  4. Patients who have any severe and/or uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including:

    1. Patients with meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, untreated brain metastases or symptomatic or unstable brain metastases. Note: Patients with stable brain metastases (defined as asymptomatic or no requirement for high-dose [defined as dexamethasone 10 mg daily or higher] or increasing dose of systemic corticosteroids) and without imminent need of radiation therapy are eligible. If applicable, patients must have completed brain radiation therapy and recovered adequately from any associated toxicity and/or complications prior to eligibility assessment. For patients who have received prior radiation therapy, post-treatment MRI scan should show no increase in brain lesion size/volume.
    2. Unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association, NYHA class III or IV), myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.
    3. Pre-existing severely impaired lung function. If a patient has a pre-existing pulmonary condition, eligible patients should have a spirometry and diffusing capacity for carbon monoxide (DLCO) that is >50% of the normal predicted value and/or O2 saturation that is >88% at rest on room air (Note: spirometry and pulmonary function tests [PFTs] not required to be performed unless clinically indicated).
    4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy.
    5. A history of malignancies other than the one under treatment unless the patient is disease-free for more than 5 years from diagnosis. Note, controlled non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, certain low grade hematologic malignancies (eg CLL, follicular lymphoma, etc), or other adequately treated carcinoma-in-situ may be eligible, after discussion with the medical monitor.
    6. Uncontrolled hypertension (systolic blood pressure ≥160 mm-Hg and/or diastolic blood pressure ≥100 mm Hg).
    7. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.
    8. Individuals with known human immunodeficiency virus (HIV) infection are excluded from this study as combination antiretroviral therapy could potentially result in significant pharmacokinetic interactions. In addition, these individuals are at increased risk of serious infections due to the immunosuppressive effects of mTOR inhibition.
    9. Active Hepatitis B or Hepatitis C, with detectable viral load.

  5. Regarding concomitant medications with significant CYP3A4 and P-gp interactions, discontinuation of strong inhibitors (eg, ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, telithromycin, and others), strong inducers (eg, rifampin, rifabutin), and known CYP3A4 substrates with a narrow therapeutic window (eg, fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, or terfenadine) is required at least 5 half lives prior to receiving the first dose of nab-sirolimus, whichever is longer.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm A: Pathogenic inactivating TSC1 alterations

Patients with pathogenic inactivating TSC1 alterations.
의약품: nab-sirolimus

Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients

다른 이름들:
  • ABI-009
실험적: Arm B: Pathogenic inactivating TSC2 alterations

Patients with pathogenic inactivating TSC2 alterations.
의약품: nab-sirolimus

Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients

다른 이름들:
  • ABI-009

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall Response Rate (ORR)
기간: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression , up to 30 months.

Based on CT or MRI scans from the time of study treatment initiation until disease progression, overall response rate (ORR) is defined as the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by independent Radiographic Review (IRR).

CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.
The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression , up to 30 months.

2차 결과 측정

결과 측정
측정값 설명
기간
Duration of Response (DOR)
기간: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.

DOR is defined as the number of months from the start of CR or PR (whichever response is recorded first) and subsequently confirmed to the first date of documented progressive disease (PD) or death using CT or MRI scans in accordance with RECIST v1.1.

CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.

PD is defined as ≥20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.
Disease Control Rate
기간: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression, up to 30 months.

Disease control rate (DCR) is defined as BOR of confirmed CR or PR (either of any duration) or SD ≥12 weeks following study treatment initiation.

CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.
The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression, up to 30 months.
Time to Response
기간: The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.

Time to response (TTR) is defined as the time from first dose of study drug to initial measurement of CR or PR, where CR or PR is subsequently confirmed.

CR is defined as disappearance of all target lesions. PR is defined as ≥30% decrease in the sum of diameters of target lesions from baseline, with no new lesions and no progression of non-target lesions.
The first response assessment is done 6 weeks (±7 days) after first treatment and should be repeated every 6 weeks (±7 days) for the first year, then every 12 weeks (±7 days) thereafter until disease progression.
Progression-free Survival
기간: From first dose of study treatment to the date of disease progression or death

Number of months from study treatment initiation to the date of disease progression (PD) or death due to any cause PD is defined as ≥20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
From first dose of study treatment to the date of disease progression or death
Overall Survival
기간: From first dose of study treatment to the date of death

Number of months from study treatment initiation to the date of death due to any cause
From first dose of study treatment to the date of death
Patient-Reported Outcome
기간: D1 of every cycle up to Cycle 24

Changes from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QOQ-C30) v3.0 scores EORTC QOQ-C30 includes functional scales (physical, role, cognitive, emotional, social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); two used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life.
D1 of every cycle up to Cycle 24
Incidence and Severity of Treatment-emergent and Treatment-related Adverse Events (AEs)
기간: Monitored continuously from signing of Informed Consent until last dose of IP (estimated up to 30 months) plus safety follow-up of 28 days after the last dose.

Incidence and severity of treatment-emergent and treatment-related AEs as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0
Monitored continuously from signing of Informed Consent until last dose of IP (estimated up to 30 months) plus safety follow-up of 28 days after the last dose.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Aadi Bioscience, Inc.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 3월 10일

기본 완료 (실제)

2024년 12월 23일

연구 완료 (실제)

2024년 12월 23일

연구 등록 날짜

최초 제출

2021년 10월 22일

QC 기준을 충족하는 최초 제출

2021년 10월 22일

처음 게시됨 (실제)

2021년 11월 2일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 26일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • TSC-007

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다